Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27529169 | 1.00 | HTR1A (0.45) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8420289 | 0.81 | HTR1A (0.46) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22612419 | 0.81 | HTR1A (0.46) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3510683 | 0.81 | HTR1A (0.46) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13778643 | 0.79 | LMNA (0.48) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| Phenylethanolamine SCHEMBL296410 | 0.79 | BLM (0.57) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9338129 | 0.79 | LMNA (0.48) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| Phenylethanolamine SCHEMBL21723498 | 0.79 | BLM (0.57) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14047172 | 0.79 | LMNA (0.48) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 | |
| Phenylethanolamine SCHEMBL7150657 | 0.79 | BLM (0.57) | HTR1AHTR7SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0406088-B1 | (Alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamide, process for its preparation and its applications | LAFON LABOR (FR) | 1994-03-16 | — | — | EP | claimed |
| EP-0406088-A1 | (Alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamide, process for its preparation and its applications | LABORATOIRE L. LAFON (FR) | 1991-01-02 | — | — | EP | claimed |
| JP-3148254-A | — | — | None | — | — | JP | disclosed |
| US-6515023-B2 | For inhibiting the aggregation of blood platelets; 3-(4-Aminomethyl-phenyl)-1-(2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl)-1 -isopropyl-urea for example | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| EP-0743063-B1 | Use of derivatives of alpha-aminomethyl-3,4-dichlorobenzyl thioacetamide for the preparation of a medicament inhibiting the recapture of dopamine and compounds for this use | LAFON LABOR (FR) | 2002-02-13 | — | — | EP | disclosed |
| US-20020007045-A1 | Thrombin receptor antagonists | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| US-6268397-B1 | ALPHA-(1-ADAMANTYLAMINOMETHYL)3,4-DICHLOROBENZYL)THIOACETAMID E AND ITS ISOMERS, AS WELL AS THE ADDITION SALTS OF THESE COMPOUNDS | LABORATOIRE. L. LAFON (FR) | 2001-07-31 | — | — | US | disclosed |
| US-6156940-A | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5795915-A | PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS | LABORATOIRE L. LAFON (FR) | 1998-08-18 | — | — | US | disclosed |
| US-5621011-A | ANTIDEPRESSANT; PROMOTE FEED INTAKE | LABORATOIRE L. LAFON (FR) | 1997-04-15 | — | — | US | disclosed |
| EP-0743063-A1 | Use of derivatives of alpha-aminomethyl-3,4-dichlorobenzyl thioacetamide for the preparation of a medicament inhibiting the recapture of dopamine and compounds for this use | LABORATOIRE L. LAFON (FR) | 1996-11-20 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0406088-B1 | (Alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamide, process for its preparation and its applications | LAFON LABOR (FR) | 1994-03-16 | — | — | EP | disclosed |
| JP-H03148254-A | (ALPHA(TERTBUTYLAMINOMETHYL)3,4-DICHLOROBENZYL)-THIOACETAMIDE, ITS PRODUCTION AND COMPOSITION CONTAINING THE SAME | LAB L LAFON SA | 1991-06-25 | — | — | JP | disclosed |
| EP-0406088-A1 | (Alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamide, process for its preparation and its applications | LABORATOIRE L. LAFON (FR) | 1991-01-02 | — | — | EP | disclosed |
| US-4117157-A | TREATMENT OF CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007045-A1 | Thrombin receptor antagonists | F2R, TBXA2R, PTAFR | HTR1A 166/4885HTR7 597/4885SLC6A2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.